Denosumab Products for Osteoporosis and Cancer-Treatment-Related Bone Loss
Customize your policy alerts
Sign up for all Hawaii Medical Service Association (HMSA) policy alerts
Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs HMSA Medicare Advantage coverage and prior authorization for Prolia and specified denosumab biosimilar products. It defines covered indications, preferred-product exception criteria, authorization durations, continuation requirements, and dosing controls.
A preferred-product grid and non-preferred product exception criteria were added.
The policy received an off-cycle revision effective October 1, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.